Condition:   Melanoma
Interventions:   Biological: dactinomycin;   Drug: melphalan;   Biological: Conditionally replicative adenovirus 3/5-delta
Sponsors:   Washington University School of Medicine;   Washington University School of Medicine
Not yet recruiting - verified February 2012

Condition:   Pleuropulmonary Blastoma
Interventions:   Drug: Vincristine;   Drug: Dactinomycin;   Drug: Cyclophosphamide;   Drug: Ifosfamide;   Drug: Doxorubicin
Sponsors:   Children's Hospitals and Clinics of Minnesota;   Children's Hospitals and Clinics of Minnesota
Recruiting - verified November 2011

Condition:   Melanoma
Intervention:   Drug: Ipilimumab, Melphalan and Dactinomycin
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Bristol-Myers Squibb
Recruiting - verified November 2011

Condition:   Sarcoma
Interventions:   Biological: cixutumumab;   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: irinotecan hydrochloride;   Drug: temozolomide;   Drug: vincristine sulfate
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Brain Cancer;   Choroid Plexus Tumors
Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Dactinomycin;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Irinotecan;   Drug: Leucovorin;   Drug: Methotrexate;   Drug: Temozolomide;   Drug: Vincristine
Sponsors:   Tufts Medical Center;   Tufts Medical Center
Recruiting - verified April 2012

Conditions:   Leukemia;   Acute Lymphoblastic Leukemia
Intervention:   Drug: Dasatinib, Mitoxantrone, Cytarabine
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Bristol-Myers Squibb
Recruiting - verified January 2012

Conditions:   Kidney Cancer;   Metastatic Cancer
Interventions:   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: vincristine sulfate;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: busulfan;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: melphalan;   Drug: vincristine sulfate;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   University Hospitals, Leicester;   National Cancer Institute (NCI);   Children's Cancer and Leukaemia Group;   Societe Francaise Oncologie Pediatrique;   European Organization for Research and Treatment of Cancer - EORTC;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria;   Swiss Group for Clinical Cancer Research;   EBMT Solid Tumors Working Party;   Children's Oncology Group
Recruiting - verified December 2011